TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

56 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Eczema / atopic dermatitis

    Molecular Signatures of Cutaneous Dupilumab Response

    Studying how dupilumab affects immune cells in eczema skin

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +1 more US site · Get directions →

    This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

    Testing whether an experimental medicine is safe and works for eczema

    📍 Northridge Clinical Trials · Northridge, CA · +3 more US sites · Get directions →

    The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

    The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Cardamom and Topical Roseomonas in Atopic Dermatitis

    Testing cardamom and a skin-applied germ to treat eczema

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems.

    ✓ Study care freePhase 2Ages 2–100Learn more →
  • Eczema / atopic dermatitis

    A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

    Testing the long-term safety and effects of a drug in people with eczema

    📍 Investigational Site · Fountain Valley, CA · +21 more US sites · Get directions →

    This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Dupilumab De-escalation in Pediatric Atopic Dermatitis

    Testing whether stopping or lowering eczema treatment works for kids

    📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →

    This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

    ✓ Study care freePhase 4Ages 1–17Learn more →
  • Fatty liver disease (NASH/MASH)

    Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

    Testing whether daily soy milk affects liver disease in children with fatty liver

    📍 Cincinnati Children's Hospital Medical Center · Cincinnati, OH · Get directions →

    A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities.

    ✓ Study care freePhase 2Ages 5–12Learn more →
  • Eczema / atopic dermatitis

    A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

    Testing a medicine for moderate to severe eczema, compared with a placebo

    📍 Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute · Phoenix, AZ · +39 more US sites · Get directions →

    This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.

    ✓ Study care freePhase 2Ages 18–100Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health - Chandler · Chandler, AZ · +30 more US sites · Get directions →

    Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse

    ✓ Study care freePhase 2Ages 30+Learn more →
  • Heart / cardiovascular disease

    Improving Coronary Vascular Health in Women

    Testing whether blood flow in heart arteries can be improved in women with HIV

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.

    ✓ Study care freePhase 2Ages 45–75WomenLearn more →
  • Eczema / atopic dermatitis

    A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

    Testing different doses of a medicine versus placebo for eczema

    📍 Inmagene Site 1 · Lancaster, CA · +14 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

    ✓ Study care freePhase 2Ages 18–74Learn more →
  • Fatty liver disease (NASH/MASH)

    Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

    Testing how SGLT2 inhibitors work for fatty liver disease in obese teens

    💵 May compensate

    📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

    ✓ Study care freePhase 2Ages 16–20Learn more →
  • Eczema / atopic dermatitis

    Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

    Testing how different doses of soquelitinib work for moderate to severe atopic dermatitis

    📍 Corvus Clinical Trials · South San Francisco, CA · Get directions →

    The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Fibrosis Lessens After Metabolic Surgery

    Testing whether metabolic surgery can reduce liver scarring in obesity

    💵 May compensate

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

    Testing a daily medicine for eczema and hair loss in people with Down syndrome

    📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →

    This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks.

    ✓ Study care freePhase 2Ages 12+Learn more →
  • Eczema / atopic dermatitis

    A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

    Checking the long-term safety and effects of an eczema medicine in people who previously studied it

    📍 Hamilton Research, LLC · Alpharetta, GA · +2 more US sites · Get directions →

    This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Lebrikizumab in Moderate-to-severe Atopic Dermatitis

    Testing a medicine called lebrikizumab for long-term improvement in eczema

    📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →

    This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    Testing efimosfermin in people with MASH-related compensated cirrhosis

    💵 May compensate

    📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Ethnic Differences in Mechanisms of Action of Dupilumab

    Studying how a common eczema treatment works differently by race

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Heart / cardiovascular diseaseLupus (SLE)

    The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Testing whether anifrolumab improves blood vessel risk markers in lupus

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

    Testing a medicine at two doses for safety and effects on fats in people with high triglycerides and

    💵 May compensate

    📍 OrsoBio Research Site · Guadalajara, Jalisco · Get directions →

    This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • Eczema / atopic dermatitis

    A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing how camoteskimab works in adults with moderate to severe eczema

    📍 AllerVie Clinical Research · Birmingham, AL · +32 more US sites · Get directions →

    This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    📍 Physioseq, LLC /ID# 267266 · Sacramento, CA · +1 more US site · Get directions →

    Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing repeat under-the-skin doses of FB825 for adult eczema

    📍 First OC Dermatology · Fountain Valley, CA · +5 more US sites · Get directions →

    This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    📍 ALS Global · Irving, TX · Get directions →

    This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Milk Thistle Clinical Trial in Pediatric NAFLD

    Testing milk thistle for children with fatty liver disease

    💵 May compensate

    📍 University Hospitals Cleveland Medical Center · Cleveland, OH · Get directions →

    Pediatric Fatty Liver disease is a growing problem in the United States and is expected to be the leading cause of Liver Transplantation in Adults in 20 years. Following lifestyle changes such as diet restrictions and exercise may be difficult to consistently maintain.

    ✓ Study care freePhase 2Ages 9–22Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

    Testing how BGE-102 affects inflammation blood tests and safety in people with obesity and heart

    📍 Site 108 · Chandler, AZ · +11 more US sites · Get directions →

    The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    Digoxin In NASH (CODIN)

    Testing digoxin for people with metabolic fatty liver inflammation

    📍 Yale New Haven Health · New Haven, CT · +1 more US site · Get directions →

    Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metabolic associated steatohepatitis (MASH), involves lifestyle interventions to promote weight loss and to treat comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    Testing how semaglutide works in people with heart failure and obesity

    📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.

    ✓ Study care freePhase 1Ages 20–80Learn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

    Testing a medicine to see its cardiovascular effects in adults on dialysis

    📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →

    This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    📍 Atd002 52021 · Oceanside, CA · +19 more US sites · Get directions →

    The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing a daily medicine for eczema severity in adults over 12 weeks

    📍 Enveda Investigative Site · Birmingham, AL · +22 more US sites · Get directions →

    The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

    Testing resmetirom in people with MASH-related liver scarring after liver transplant

    💵 May compensate

    📍 University of California San Diego · La Jolla, CA · +15 more US sites · Get directions →

    A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Obesity / overweightType 2 diabetesHeart / cardiovascular disease

    Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

    Testing the diabetes medicine pioglitazone in people with type 2 diabetes, obesity, and heart

    📍 Texas Diabetes Institute/UH · San Antonio, TX · Get directions →

    Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.

    ✓ Study care freePhase 4Ages 30–70Learn more →
  • Eczema / atopic dermatitis

    A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

    Testing two medicines for safety and effects in people with eczema

    📍 Allervie Clinical Research · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Effects of Treatments on Atopic Dermatitis

    Testing treatments for eczema (atopic dermatitis)

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S.

    ✓ Study care freePhase 2Ages 2–50Learn more →
  • Heart / cardiovascular diseaseDementia / Alzheimer's

    Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

    Testing whether lowering cholesterol in older adults affects heart and memory outcomes

    📍 University of Alabama at Birmingham · Birmingham, AL · +37 more US sites · Get directions →

    PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo.

    ✓ Study care freePhase 4Ages 75+Learn more →
  • Heart / cardiovascular disease

    Ertugliflozin in Chronic Heart Failure

    Testing ertugliflozin and other medicines for heart failure symptoms

    📍 Yale School of Medicine · New Haven, CT · Get directions →

    The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Low-Dose Pioglitazone in Patients With NASH (AIM 2)

    Testing a low-dose diabetes medicine to see effects on liver changes in NASH

    💵 May compensate

    📍 University of Florida · Gainesville, FL · Get directions →

    To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

    ✓ Study care freePhase 2Ages 21–75Learn more →
  • Heart / cardiovascular disease

    Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

    Testing stem cell treatment for safety and effects on heart disease

    📍 Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites · Culver City, CA · Get directions →

    This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

    Studying how vitamin C affects blood vessel function in obese adults with insulin resistance and

    📍 University of Kansas Medical Center · Kansas City, KS · Get directions →

    The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD).

    ✓ Study care freePhase 1Ages 35–65Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure

    PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

    Testing timing of blood pressure medicines in people with obesity and high blood pressure

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

    Testing how dupilumab affects sleep, itching, and body clock in children with moderate to severe

    📍 Lurie Children's Hospital/Northwestern University · Chicago, IL · Get directions →

    Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

    ✓ Study care freePhase 4Ages 6–17Learn more →
  • Eczema / atopic dermatitis

    Dupixent and Narrowband UVB for Atopic Dermatitis

    Testing dupilumab plus narrowband UVB light for eczema over 24 weeks

    📍 Eczema Treatment Center of New Jersey · East Windsor, NJ · Get directions →

    24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Quantifying Hepatic Mitochondrial Fluxes in Humans

    Measuring liver energy activity in people with type 2 diabetes before and after 16 weeks of insulin

    📍 Texas Diabetes Institute - University Health System · San Antonio, TX · +1 more US site · Get directions →

    In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

    Testing whether semaglutide can prevent weight gain after liver transplant

    📍 Virginia Commonwealth University · Richmond, VA · Get directions →

    In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Soluble Fibre Supplementation in NAFLD

    Testing a fiber supplement to see how it affects liver fat in children with non-alcoholic fatty

    📍 McMaster University Medical Center · Hamilton, Ontario · Get directions →

    The FIND study will look at the effect of a nutritional mixed fibre supplement, oligofructose and inulin (OF+INU), on children with non-alcoholic fatty liver disease. In this randomized, double- blind controlled trial, subjects will be given a supplement, in the form of oral pills, and will have bloodwork performed, their diets analyzed, and liver fat measured at several timepoints.

    ✓ Study care freePhase 2Ages 8–17Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

    This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

    Testing thyroid hormone to treat advanced fatty liver disease in veterans

    📍 Harry S. Truman Memorial, Columbia, MO · Columbia, MO · Get directions →

    Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem. It is more common in the military and Veteran population compared to the general US population.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

    Testing tirzepatide to see if it slows plaque buildup in heart arteries in people with type 2

    📍 Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) · Torrance, CA · Get directions →

    A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.

    ✓ Study care freePhase 4Ages 40–80Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

    Testing dapagliflozin with standard care on heart and lung function and blood metabolites in chronic

    📍 Northwestern University · Chicago, IL · Get directions →

    The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

    Testing tirzepatide to see effects on muscle and blood vessels in older adults with obesity and

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health.

    ✓ Study care freePhase 2Ages 50+Learn more →
  • Eczema / atopic dermatitis

    Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

    Testing medicines for safety and how well they work for moderate to severe eczema

    📍 Novartis Investigative Site · Birmingham, AL · +21 more US sites · Get directions →

    This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

    ✓ Study care freePhase 2Ages 18–100Learn more →